Test Price
2,800 AED✅ Home Collection Available
DAG1 Gene Muscular Dystrophy-Dystroglycanopathy (Limb-Girdle), Type C9 Genetic Test in UAE
تحليل الجين DAG1 لضمور العضلات الحزامي الطرفي من النوع C9 في الإمارات | 2800 درهم | معتمد من هيئة الصحة بدبي
ISO 9001:2015
Cert: INT/EGQ/2509DA/3139
Facility License: 9834453
Executive Summary – 2026 Clinical Confidence
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO-Accredited NGS with Sanger validation.
- Premium Logistics: Paid Hospital-Grade Home Collection via ISO Certified Cold-Chain Phlebotomy (8 AM – 11 PM).
- Clinical Guidance: Telephonic Post-Test Clinical Guidance in result interpretation by a neurologist.
- Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
Compliant with UAE PDPL, Federal Decree-Law No. 41 of 2024 (Art. 87), and CDS Law 2026 (Minors).
خلاصة تنفيذية
يضمن اختبارنا دقة تشخيصية بنسبة 99.9٪ عبر تقنية التسلسل الجيني (NGS) المعتمدة وفق ISO 9001:2015، مع خدمة سحب الدم المنزلي المتميزة المبردة، واستشارة وراثية شاملة بعد النتيجة، وتوجيه سريري هاتفي.
Test Overview
The DAG1 gene NGS test identifies pathogenic variants causing limb‑girdle muscular dystrophy‑dystroglycanopathy type C9, a progressive autosomal recessive disorder. يكشف اختبار الجين DAG1 الطفرات المسببة لضمور العضلات الحزامي الطرفي من النوع C9.
| Feature | Our Test (NGS Gold Standard) | Closest Alternative (Sanger Only) |
|---|---|---|
| Precision | 99.9% analytical sensitivity, full gene coverage + copy number detection | Limited to targeted regions, may miss deep intronic variants |
| Methodology | NGS (Next-Generation Sequencing) with orthogonal Sanger confirmation of all clinically significant variants | Sanger sequencing of coding exons only |
| Turnaround Time | 3 to 4 Weeks | 6–8 Weeks |
| Clinical Depth | Interpretation aligned with 2026 ACMG/ClinGen guidelines and UAE genetic counselling standards | Basic variant report without comprehensive clinical context |
Physician Insight & Safety Protocol
“As a neurologist with extensive experience in neuromuscular genetics, I understand the emotional weight of waiting for a diagnosis that could reshape family planning and care. This NGS-based test provides a definitive molecular answer, reducing diagnostic odyssey and enabling proactive management. However, a negative result does not exclude other myopathies; clinical correlation remains essential.”
— Dr. PRABHAKAR REDDY, DHA License 61713011
⚠️ Do not discontinue prescribed medication without consulting your doctor.
Exclusion Criteria & ER Red Flags
- Not for emergency diagnosis of acute muscular deterioration.
- Minors below 18 years require a genetic counselling session and legal guardian consent per CDS Law 2026.
- Prenatal/preimplantation use without UAE medical board approval is not permitted.
- Not validated as a stand‑alone screening in asymptomatic individuals without a confirmed family mutation.
Seek immediate emergency care if you experience:
- Rapidly worsening muscle weakness or inability to stand.
- Breathing difficulty, choking, or chest pain.
- Loss of consciousness or cardiac arrhythmia.
Patient FAQ & Clinical Guidance
Q1: What is the DAG1 gene test and why is it performed?
It identifies DAG1 gene mutations responsible for limb-girdle muscular dystrophy type C9, guiding targeted management and genetic counseling. This diagnostic test is recommended for individuals with progressive proximal muscle weakness, elevated CK, and a family history suggestive of dystroglycanopathy. Results enable accurate prognosis assessment, reproductive risk counselling, and enrollment in clinical trials.
يحدد هذا الاختبار الطفرات في جين DAG1 المسببة لضمور العضلات الحزامي الطرفي من النوع C9، مما يوجه العلاج والاستشارة الوراثية. يُوصى به للمرضى الذين يعانون من ضعف عضلي قريب مترقٍّ وارتفاع في إنزيم CK مع تاريخ عائلي إيجابي.
Q2: How is the test performed and what sample is required?
Home phlebotomy collects a blood sample; NGS-based analysis provides results within three to four weeks. A certified phlebotomist visits your home (8 AM – 11 PM) to draw 4 mL of whole blood in an EDTA tube; alternative accepted samples are extracted DNA or a dried blood spot on an FTA card. The sample is transported under cold chain to our ISO 9001:2015 lab for high‑depth sequencing.
يتم جمع عينة دم في المنزل عبر الفصد المنزلي؛ وتحليل NGS يعطي النتائج خلال ثلاثة إلى أربعة أسابيع. نستقبل الدم الكامل أو الحمض النووي المستخلص أو بقعة دم جافة على بطاقة FTA.
Q3: Will my insurance cover this?
Direct insurance verification via WhatsApp; most UAE plans cover genetic testing for medically indicated cases. We facilitate pre‑authorization by liaising with major insurers (Daman, Thiqa, Neuron, etc.) after you send a copy of your referral via +971 54 548 8731. Coverage typically applies when neurologist‑ordered and supported by clinical findings.
نتحقق من التغطية التأمينية مباشرة عبر الواتساب؛ معظم خطط التأمين في الإمارات تغطي الاختبارات الجينية للحالات الطبية المبررة. نقوم بالتحقق المسبق لضمان خصم المطالبة السلس.
+971 54 548 8731 | Confidential & PDPL-Compliant
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians